FDA clears Visx' WaveScan system:
This article was originally published in Clinica
Executive Summary
Visx has received US FDA 510(k) clearance for a device that will allow doctors to instantly measure refractive aberrations during laser vision corrective surgery. The WaveScan wavefront system uses optics that project light into the eye and then analyse the returning wavefront using a Hartmann-Shack sensor, which contains thousands of tiny lenslets. The system will produce a WavePrint, similar to a "fingerprint" of the eye, which illustrates an accurate assessment of the patient's refractive errors, said the Santa Clara, California-based company.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.